The weight-loss world is on the brink of a major shake-up.
Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several other countries set to follow in the months ahead.
The move is expected to unleash a wave of cheaper alternatives, dramatically widening access to the blockbuster diabetes and obesity treatments.
Here’s everything you need to know — including why Americans shouldn’t start celebrating just yet.
What’s happening in India?
Novo Nordisk’s patent on semaglutide — the active ingredient in Ozempic and Wegovy — expires in India on Friday. (Mounjaro and Zepbound are brand names for tirzepatide, a similar drug patented by Eli Lilly.)
That will end the Danish drugmaker’s monopoly on selling the drugs in the country, clearing the way for the first generic versions to hit the market as soon as this weekend.
Right now, the drugs come with a hefty price tag. Ozempic typically runs 8,800 to 11,000 rupees ($95–$119) per month, while Wegovy can cost 10,000 to 16,000 rupees ($108–$173), depending on the dose.
Indian generic makers haven’t revealed their prices yet, but Reuters reports they could be 50% to 60% cheaper. According to the New York Times, analysts say they could eventually go for as little as $15 a month.
Which countries will get generics next?
Novo Nordisk’s patents on semaglutide are set to expire in major markets around the world over the coming months. Generic versions are expected to roll out soon in China, Brazil, Turkey and South Africa.
The company’s patent already expired in Canada, but cheaper rivals aren’t expected to hit pharmacies until mid-2026.
“The affordability that will come with generics and biosimilars will be hugely game-changing,” Angie Jackson-Morris, director of program development and strategy at the World Obesity Federation, told Bloomberg in January.
Facing a wave of copycats, Novo Nordisk has already cut prices for Ozempic and Wegovy in India and China, aiming to hold its edge in the global diabetes and obesity markets.
Officials told the New York Times that the company is also exploring strategies to stay competitive in countries where generics will be available, including positioning the original drugs as a premium brand.
When will we get cheap generics for Ozempic and Wegovy in the US?
Americans will have to wait years before generic semaglutide hits the market.
Novo Nordisk will keep its patents on Ozempic and Wegovy in the US until 2032. It also holds exclusive rights in Japan and Europe until 2031, according to the company’s 2024 earnings report.
In the meantime, compounded — and often cheaper — versions of the drugs are available in the US, but they aren’t FDA-approved generics and may carry additional safety risks.
Can Americans import generic semaglutide from other countries?
In most cases, the answer is no.
It’s illegal for Americans to import prescription drugs that haven’t been approved by the Food and Drug Administration for use and sale in the US, according to Customs and Border Protection.
That includes medications cleared by regulators abroad — like the generic versions expected to hit the market this weekend in India.
There are some limited exceptions. The FDA may allow personal importation in certain cases, such as for the treatment of a serious condition with no major safety concerns or when effective treatment isn’t available in the US.
But those situations are rare. Given the long list of potential side effects linked to semaglutide, along with the availability of branded Ozempic and Wegovy in the US, it’s unlikely the agency would allow generics to be imported.
If you’re caught trying to illegally import prescription drugs into the US, they’ll typically be seized by the FDA and CBP.
And the consequences can be steep — including hefty fines and even prison time.
